•Defining partial response in inflammatory bowel disease: a Delphi consensus and economic evaluation
•Real-world efficacy of ustekinumab and vedolizumab in pediatric and young adult patients with inflammatory bowel disease
•Investigation of Appropriate Telemedicine for Patients with Inflammatory Bowel Disease
•Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study
•Drp1-mediated mitochondrial fission exacerbates inflammatory responses in intestinal epithelial cells: A potential therapeutic target for IBD
